Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer
9.11.2022 15:27:00 EET | Business Wire | Press release
Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer. Christopher will report to Jorge Bartolome, CEO of Areteia Therapeutics, effective immediately.
Christopher is a seasoned industry executive with over 20 years of experience in public and private life science companies. Most recently, Christopher served as Chief Financial Officer at Pebble Labs, a biotech company creating safe and effective biological solutions to sustainably protect yields and quality in food production, where he led financial operations, strategic planning, and business development.
Prior to Pebble Labs, Christopher served as CFO and founding member of Regado Biosciences’ executive team. He was responsible for the company’s finance and accounting functions, as well as raising $260M in private and public equity financings. Christopher managed the S1 process culminating with the company’s successful IPO.
“I am delighted to be welcoming another experienced member to the executive team at Areteia Therapeutics,” said Jorge Bartolome, CEO of Areteia Therapeutics. He added “Chris will play an essential role in fulfilling our company’s mission to put asthma patients in better control of their disease and lives.”
About Areteia Therapeutics
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.
About Dexpramipexole
Dexpramipexole is an oral small molecule in phase 3 development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase 2 study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005055/en/
Contact information
Tamsin Berry
Tamsin.Berry@areteiatx.com
Mark Kreston
Mark.Kreston@areteiatx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Appoints Veli-Matti Mattila as Chairman to Support the Next Phase of Industrial Scale-Up3.6.2026 09:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has appointed renowned Finnish business leader Veli-Matti Mattila as Chairman of the Board effective immediately. Mattila brings decades of international leadership experience and board expertise to support Coolbrook’s next phase of commercial growth, industrial execution, and global scale-up. Veli-Matti Mattila is one of Finland’s most experienced technology business leaders, having served as CEO of Elisa Corporation from 2003 to 2024, following a long international career at Ericsson, where he held several senior leadership roles, including President of Ericsson Finland and COO & Deputy Head of Market Unit, Nordic & Baltic. He also spent four years in the U.S. and a period of time in Switzerland during his stint at Ericsson. He currently serves as Chairman of Orion Corporation and Enento Group, and has previously chaired Confederation of Finnish Industries (EK) and has
Airgain Expands Public Safety and Utility Connectivity Portfolio with FirstNet, Built with AT&T3.6.2026 00:56:00 EEST | Press release
Airgain, Inc. (NASDAQ: AIRG), a leading provider of advanced wireless connectivity solutions, today announced the continued expansion of its mission-critical connectivity portfolio with FirstNet®, Built with AT&T – America’s public safety network – to support reliable, high-performance communications for public safety agencies, utilities and field operations across the United States. Growing its public safety connectivity capabilities, Airgain recently added the MegaFi 2™ and MegaGo 2™ to its portfolio. As FirstNet MegaRange™ solutions, which use High Power User Equipment (HPUE) technology, the two routers transmit with 6x the power exclusively on Band 14, nationwide, high-quality spectrum set aside by the government for public safety on FirstNet. This helps support reliable communications in remote areas and through signal-blocking materials like glass, concrete and metal. The addition of MegaFi 2™ and MegaGo 2™ strengthens Airgain’s growing AirgainConnect® portfolio, which also inclu
Fi Expands International Footprint to 38 Countries Worldwide2.6.2026 20:25:00 EEST | Press release
Fi, the leader in smart pet technology, today announced a major international expansion, bringing its AI-powered GPS pet wearables and connectivity network to 38 countries across North America and Europe. Fi devices are now available for purchase in 29 markets, including newly added countries such as Finland, Sweden, Denmark, Austria, Belgium, the Netherlands, Romania, Slovakia, and Latvia. Through Fi's international connectivity network, customers can also use Fi in Switzerland, Norway, Liechtenstein, Iceland, and Turkey, bringing Fi's total coverage footprint to 38 countries. The expansion reflects growing demand from pet owners who want reliable connectivity and health insights, whether they're at home or traveling abroad. "Wherever your pet roams, Fi should work," said Jonathan Bensamoun, Founder and CEO of Fi. "As more pet owners travel internationally and expect seamless connectivity, we're expanding Fi's footprint to help them stay connected to their pets across more of Europe a
XFolio AI Acquires Absolute Payment Solutions to Unify Treasury and Payments for UK Corporates2.6.2026 20:16:00 EEST | Press release
XFolio AI (xfolio.ai), a Paris-based treasury and cash management technology group, has acquired Absolute Payment Solutions (APS) (https://www.absolutepayments.com/), one of a select number of Pay.UK-accredited Bacs service providers in the UK. This acquisition creates an integrated platform spanning Bacs and all payment types, open banking, risk management, and treasury—giving UK corporates of all sizes the tools to manage cash and execute payments in one place. APS’s Bacs accreditation underpins payment services relied upon daily by organisations across both the public and private sectors, from SMEs running payroll and direct debit collections to large corporates processing high-volume payment flows. While enterprise payment platforms often demand significant scale and budget, and lighter solutions trade capability for speed of setup, APS and XFolio together deliver accredited Bacs infrastructure combined with advanced treasury intelligence across SWIFT, API, H2H, and EBICS rails—wit
Amazfit Introduces a New Era of Hybrid Training with Balance 3 and Balance Ultra2.6.2026 20:00:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today unveiled the Amazfit Balance 3 and Amazfit Balance Ultra, the newest additions to the Balance series and the hero watches for Amazfit’s new Hybrid Training System, connecting performance tracking with intelligent training guidance through the Zepp App. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602329170/en/ Built around how modern athletes train today, Balance 3 and Balance Ultra are designed for people balancing strength, endurance, recovery, work, stress, and daily life. The devices serve as the engine layer of the connected Hybrid Training ecosystem, capturing how users train, recover, and respond over time. The products were unveiled at a launch event in New York during a panel hosted by leading voices from the fitness and HYROX community. Built around how modern athletes train today, Balance 3 and Balance Ultra are designed for people bal
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom